Lisocabtagene maraleucel

BIOLOGICAL19 trials

Sponsors

Celgene Corp., Bristol-Myers Squibb Services Unlimited Company, Juno Therapeutics, a Subsidiary of Celgene, NeoImmuneTech, Fred Hutchinson Cancer Center

Conditions

Aggressive B-cell NHLB-cell LymphomasC-MYC/BCL2 Double-Hit High-Grade B-Cell LymphomaC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaChronic Lymphocytic LeukaemiaChronic Lymphocytic Leukemia (CLL)DLBCL, Nos Genetic SubtypesDe Novo or Transformed Indolent B-cell Lymphoma

Phase 1

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

CompletedNCT05075603

NeoImmuneTechRecurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +2

Start: 2021-08-06End: 2025-03-12Updated: 2025-10-23

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Active, not recruitingNCT05359211

Fred Hutchinson Cancer CenterRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma +6

Start: 2022-12-08End: 2026-09-04Updated: 2026-03-20

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

RecruitingNCT07098364

Fred Hutchinson Cancer CenterRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma +9

Start: 2025-12-27End: 2043-10-04Target: 33Updated: 2026-01-14

Phase 2

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

CompletedNCT03483103

Juno Therapeutics, a Subsidiary of CelgeneLymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Nonhodgkin +1

Start: 2018-07-27End: 2022-12-01Updated: 2023-12-20

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

CompletedNCT03744676

Juno Therapeutics, a Subsidiary of CelgeneImmune System Disorder, Immunoproliferative Disorders, Lymphatic Diseases +7

Start: 2018-11-29End: 2023-09-22Updated: 2025-02-27

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Active, not recruitingNCT05583149

Patrick C. Johnson, MDAggressive B-cell NHL, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma +10

Start: 2023-03-01End: 2029-03-01Updated: 2026-01-29

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

RecruitingNCT05633615

SWOG Cancer Research NetworkDiffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma +4

Start: 2023-06-12End: 2030-06-30Target: 396Updated: 2026-02-02

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Active, not recruitingNCT05672173

City of Hope Medical CenterRecurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome

Start: 2023-06-02End: 2026-09-10Updated: 2026-06-09

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

RecruitingNCT05873712

Aseel AlsouqiRecurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Non-Hodgkin Lymphoma +5

Start: 2023-07-28End: 2026-12-31Target: 24Updated: 2026-03-03

LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS

RecruitingCTIS2023-504201-36-00

Celgene Corp.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.

Start: 2018-12-21Target: 214Updated: 2025-10-27

A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) (Transcend FL)

Not yet recruitingCTIS2024-510966-18-00

Celgene Corp.Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)

Target: 99Updated: 2025-08-25

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

RecruitingNCT07194980

Fred Hutchinson Cancer CenterRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start: 2026-08-01End: 2029-10-20Target: 20Updated: 2026-07-10

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

RecruitingCTIS2025-521144-38-00

Bristol-Myers Squibb Services Unlimited CompanyPrimary Central Nervous System Lymphoma

Start: 2025-12-23Target: 31Updated: 2025-11-21

GLORY: Glofit-GemOx With Liso-Cel For Lymphoma

Not yet recruitingNCT07711483

Massachusetts General HospitalB-cell Lymphomas, Large B-cell Lymphoma, Lymphoma +1

Start: 2026-10-14End: 2030-10-01Target: 56Updated: 2026-07-17

Phase 3

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

RecruitingNCT07188558

Lyell Immunopharma, Inc.Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed +6

Start: 2026-01-12End: 2032-01-01Target: 400Updated: 2026-06-08

Unknown Phase

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

RecruitingNCT06357754

Bristol-Myers SquibbChronic Lymphocytic Leukaemia, Multiple Myeloma, Non-Hodgkin Lymphoma

Start: 2023-10-06End: 2038-10-06Target: 50Updated: 2026-01-22

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

RecruitingNCT06788639

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Start: 2025-02-04End: 2044-06-30Target: 300Updated: 2025-02-24

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

RecruitingNCT06788652

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyMantle Cell Lymphoma (MCL)

Start: 2025-02-04End: 2044-09-30Target: 300Updated: 2025-02-24

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

RecruitingNCT06794268

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyFollicular Lymphoma

Start: 2025-02-04End: 2044-08-31Target: 300Updated: 2025-02-24

Related Papers

Longitudinal safety of lisocabtagene maraleucel (liso-cel) in patients (pt) with second-line or later (2L+) large B-cell lymphoma (LBCL).

Journal of Clinical Oncology2026-05-27

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Blood2025-11-03

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Blood2025-11-03

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Blood2025-11-03

Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.

Journal of Clinical Oncology2025-05-28

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Blood Advances2025-04-305 citations

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood2024-11-056 citations

Comparative efficacy of lisocabtagene maraleucel in the PILOT study <i>versus</i> second-line chemotherapy regimens in the real world

Haematologica2024-10-311 citations

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Blood Advances2024-09-3013 citations

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Blood2023-11-0214 citations

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

Blood2023-11-021 citations

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

Blood2023-11-02

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study

Haematologica2023-08-3011 citations

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood2022-11-155 citations

Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

Blood2022-11-153 citations

A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood2022-11-152 citations

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Blood2022-11-152 citations

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy

Blood Advances2022-11-0422 citations

Expansion of CAR-T Cells in Vivo With Long-Acting Interleukin-7 Analog

Oncology Times2022-08-17

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

2022-07-12170 citations

16 more papers not shown